🔍
Radiation Sensitization Agents for Prostate Cancer
Case ID:
C11146
Report of Invention:
6/17/2010
Web Published:
2/24/2017
Radiation Sensitization Agents for Prostate Cancer
JHU REF: [C11146]
Invention novelty:
A new mechanism to selectively sensitize the prostate to radiation therapy by knocking down DNA repair gene transcripts.
Value Proposition:
Current dose-escalated radiation therapy for localized prostate cancer treatment has increased the risk of injury of surrounding non-cancerous tissue due to its non-targeting application. Thus, there is a great need for the development of tissue-selective and radiation-sensitizing agents. This technology can solve the problem of broad or non-selective radiation and improve the result of radiation therapy in localized and metastatic prostate cancer. The other advantages include:
Higher tissue-selective targeting
Lower levels of ionizing radiation
Fewer adverse effects from injury to surrounding normal tissues
Technical Details:
Johns Hopkins researchers have identified six target genes in DNA-repair pathway for prostate cancer radiation sensitization by performing a high-throughput siRNA screen. They found these targets including DNA Protein Kinase and their corresponding siRNAs were conjugated to PSMA-targeting RNA aptamers in short-hairpin format (shRNA) and formed Aptamer-DNA-PK-shRNA chimeras which showed PSMA selective targeting to prostate cancer cells. In addition, intratumoral injection of the chimeras significantly showed specific gene knock-down and enhanced ionizing radiation therapeutic response in radiation therapy. They also found some similar results when they applied the same approach to human prostate tissue. Based on these results, they have demonstrated that radiation-sensitizing chimeras will effectively improve radiation therapy for high-risk localized prostate cancer.
Looking for Partners:
To develop and commercialize the technology as a therapeutic agent which is used to selectively sensitize the prostate to radiation therapy
Stage of Development
:
Pre-Clinical
Data Availability:
In vivo
and
In vitro
data
Patent Status:
PCT WO 2012/012710
Publication(s)/Associated Cases:
J Clin Invest. 2011 Jun;121(6):2383-90.
Patent Information:
Title
App Type
Country
Serial No.
Patent No.
File Date
Issued Date
Expire Date
Patent Status
RADIATION SENSITIZATION AGENTS FOR PROSTATE CANCER
PCT: Patent Cooperation Treaty
United States
13/811,442
9,029,340
1/22/2013
5/12/2015
7/22/2031
Granted
Direct Link:
https://jhu.technologypublisher.com/technology/24231
Inventors:
Category(s):
Clinical and Disease Specializations, Clinical and Disease Specializations > Men's Health, Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities,
Get custom alerts for techs in these categories/from these inventors:
Subscribe for JHTV Updates
For Information, Contact:
Vera Sampels
vsampel2@jhu.edu
410-614-0300
Save This Technology:
Bookmark this page
Download as PDF
JHTV Home
|
Search
|
Login/Subscribe
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by
Inteum